Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
FIGURE: 1 / 13
This antibody recognizes amino acid sequence-independent oligomers of proteins or peptides. A11 does not recognize monomers or mature fibers of proteins or peptides. A11 reacts with soluble AB42 oligomers and does not react with soluble low molecular weight AB40 or AB40 fibrils. A11 recognizes oligomeric species of several other amyloidogenic polypeptides including AB42, human insulin, prion, polyglutamine, lysozyme, alpha-synuclein and yeast prion Sup35.
Oligomeric AB42 is recommended as a positive control, monomeric and fibrillar AB42 as negative controls.
Amyloid beta oligomers are aggregates of the amyloid beta peptide, which is derived from the amyloid precursor protein (APP) through enzymatic cleavage. These oligomers are considered to be neurotoxic and have been implicated in the pathogenesis of Alzheimer's disease. Structurally, these oligomers can vary in size and form, ranging from dimers to large aggregates, and their formation is influenced by factors such as the peptide concentration, pH, and presence of metals. Functionally, these oligomers disrupt cellular processes, leading to synaptic dysfunction, oxidative stress, and ultimately neuronal death. They exert their toxic effects by interacting with cell membranes, forming pores, and triggering intracellular signaling pathways that result in neurodegeneration. The exact mechanisms by which Amyloid beta oligomers contribute to Alzheimer's disease are still under investigation, but they are a key focus of therapeutic strategies aimed at mitigating the progression of the disease.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: ABPP; AG; Alzheimer disease amyloid A4 protein homolog; Alzheimer disease amyloid protein; amyloid A4; amyloid beta; amyloid beta (A4) precursor protein; amyloid beta A4 protein; amyloid beta precursor protein (ABPP); amyloid beta protein; amyloid beta-protein precursor; Amyloid precursor protein; amyloid protein; Amyloid-beta (A4) precursor protein; Amyloid-beta A4 protein; Amyloid-beta precursor protein; Amyloidogenic glycoprotein; APP; APPI; appican; beta-amyloid A4; beta-amyloid peptide; beta-amyloid peptide(1-40); beta-amyloid peptide(1-42); beta-amyloid precursor protein; Cerebral vascular amyloid peptide; CVAP; peptidase nexin-II; PN-II; PreA4; protease nexin II; Protease nexin-II; testicular tissue protein Li 2; unnamed protein product
Gene Aliases: A4; AAA; ABETA; ABPP; AD1; Adap; Ag; alpha-sAPP; APP; APPI; betaApp; CTFgamma; CVAP; E030013M08Rik; PN-II; PN2; preA4
UniProt ID: (Human) B2R5V1, (Rat) P08592, (Mouse) P12023
Entrez Gene ID: (Human) 351, (Rat) 54226, (Mouse) 11820
If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Learn more
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support